Aspreva Announces Fast-Track Designation Granted by the FDA for CellCept in Lupus Nephritis (T-Net British Columbia)
Vancouver, BC, June 7, 2007--(T-Net)--Aspreva Pharmaceuticals (NASDAQ: ASPV; TSX: ASV) today announced that the U.S. Food and Drug Administration has granted Fast Track designation for CellCept (mycophenolate mofetil, MMF) for the treatment of lupus nephritis.

India's Strides Arcolab gets FDA nod for two HIV/AIDS new drug applications (Sharewatch)
MUMBAI (Thomson Financial) - India's Strides Arcolab Ltd said it has received tentative approvals from the US Food and Drug Administration for two new drug applications for fixed-dose combination of Lamivudine/Stavudine in HIV/AIDS treatment segment.

FROVA (R) Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of ... (RedNova)
Endo Pharmaceuticals Inc., a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc.